Huanling Zhu

1.2k total citations
48 papers, 613 citations indexed

About

Huanling Zhu is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Huanling Zhu has authored 48 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 23 papers in Genetics and 11 papers in Immunology. Recurrent topics in Huanling Zhu's work include Chronic Myeloid Leukemia Treatments (19 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Acute Lymphoblastic Leukemia research (9 papers). Huanling Zhu is often cited by papers focused on Chronic Myeloid Leukemia Treatments (19 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Acute Lymphoblastic Leukemia research (9 papers). Huanling Zhu collaborates with scholars based in China, United States and Italy. Huanling Zhu's co-authors include Ting Liu, Wentong Meng, Bing Xiang, Bing Long, Xiao‐Jun Huang, Jianda Hu, He Huang, Jianmin Wang, Ting Niu and Yun Xie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Huanling Zhu

39 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huanling Zhu China 12 230 194 175 138 132 48 613
Seiichiro Katagiri Japan 14 207 0.9× 199 1.0× 116 0.7× 67 0.5× 49 0.4× 59 498
Junichi Ueyama Japan 11 204 0.9× 162 0.8× 53 0.3× 171 1.2× 94 0.7× 35 545
Ilana Zalcberg Brazil 14 297 1.3× 246 1.3× 216 1.2× 231 1.7× 54 0.4× 53 739
A. Krämer Germany 14 229 1.0× 323 1.7× 83 0.5× 251 1.8× 51 0.4× 31 723
Takero Shindo Japan 12 236 1.0× 180 0.9× 154 0.9× 138 1.0× 41 0.3× 59 620
Klaus Fenchel Germany 14 133 0.6× 258 1.3× 154 0.9× 340 2.5× 65 0.5× 31 855
Raymond Liang Hong Kong 13 214 0.9× 314 1.6× 167 1.0× 281 2.0× 188 1.4× 28 930
Jens Freiberg‐Richter Germany 13 523 2.3× 76 0.4× 231 1.3× 236 1.7× 58 0.4× 27 752
Samah Abd Elhamid Egypt 13 71 0.3× 132 0.7× 152 0.9× 97 0.7× 83 0.6× 26 522
Daichi Inoue Japan 16 482 2.1× 473 2.4× 212 1.2× 81 0.6× 40 0.3× 55 864

Countries citing papers authored by Huanling Zhu

Since Specialization
Citations

This map shows the geographic impact of Huanling Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huanling Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huanling Zhu more than expected).

Fields of papers citing papers by Huanling Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huanling Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huanling Zhu. The network helps show where Huanling Zhu may publish in the future.

Co-authorship network of co-authors of Huanling Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Huanling Zhu. A scholar is included among the top collaborators of Huanling Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huanling Zhu. Huanling Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Lu, Weiming Li, Na Xu, et al.. (2024). Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. 131(1). e35652–e35652. 1 indexed citations
3.
Sun, Hui, Chunyan Chen, Minghui Duan, et al.. (2024). Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia. Haematologica. 109(12). 3965–3974. 2 indexed citations
4.
Zhang, Yanli, Huanling Zhu, Na Xu, et al.. (2024). Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML). Blood. 144(Supplement 1). 480–480. 1 indexed citations
5.
6.
7.
Gale, Robert Peter, Yanli Zhang, Xiaoli Liu, et al.. (2021). Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. Frontiers in Psychiatry. 12. 679932–679932. 3 indexed citations
8.
Luo, Hongmei, Yuhuan Zheng, Ting Niu, et al.. (2020). Low-dose ruxolitinib shows effective in treating myelofibrosis. Annals of Hematology. 100(1). 135–141. 3 indexed citations
9.
10.
Liu, Ting, Yongqian Jia, Ting Niu, et al.. (2019). Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution. Blood. 134(Supplement_1). 5384–5384.
11.
Zhao, Li, Huanling Zhu, Bing Han, et al.. (2018). Influence of genetic polymorphisms of IL23R, STAT3, IL12B, and STAT4 on the risk of aplastic anemia and the effect of immunosuppressive therapy. Annals of Hematology. 97(4). 685–695. 5 indexed citations
12.
Qu, Ying, et al.. (2018). MiR-659-3p regulates the progression of chronic myeloid leukemia by targeting SPHK1.. PubMed. 11(5). 2470–2478. 11 indexed citations
13.
Luo, Hongmei, Yu Qin, Frederic J. Reu, et al.. (2016). Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. Journal of Hematology & Oncology. 9(1). 125–125. 17 indexed citations
14.
15.
Liu, Hongying, et al.. (2014). A Paroxysmal Nocturnal Haemoglobinuria Progress with Waldenström Macroglobulinemia Along with T Cell Monoclonal Expansion. Indian Journal of Hematology and Blood Transfusion. 30(S1). 227–231.
16.
Yang, Fan, Huanling Zhu, Chuan He, et al.. (2012). Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian Journal of Hematology and Blood Transfusion. 30(2). 97–104. 5 indexed citations
17.
18.
Huang, Xiao‐Jun, Huan Chen, Mingzhe Han, et al.. (2012). Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Micafungin versus Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients undergoing Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 18(10). 1509–1516. 58 indexed citations
19.
Long, Bing, et al.. (2011). Activation of the hedgehog pathway in chronic myelogeneous leukemia patients. Journal of Experimental & Clinical Cancer Research. 30(1). 8–8. 53 indexed citations
20.
Xie, Yun, et al.. (2010). Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. Journal of Viral Hepatitis. 18(12). 877–883. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seiichiro Katagiri Breakdown of academic impact, for papers by Junichi Ueyama Breakdown of academic impact, for papers by Ilana Zalcberg Breakdown of academic impact, for papers by A. Krämer Breakdown of academic impact, for papers by Takero Shindo Breakdown of academic impact, for papers by Klaus Fenchel Breakdown of academic impact, for papers by Raymond Liang Breakdown of academic impact, for papers by Jens Freiberg‐Richter Breakdown of academic impact, for papers by Samah Abd Elhamid Breakdown of academic impact, for papers by Daichi Inoue
Rankless by CCL
2026